Trial Profile

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2026 According to an Arbor Biotechnologies media release, Phase 1/2 redePHine clinical study to be highlighted at the upcoming 15th International Hyperoxaluria Workshop on June 26th, 2026 and John Lieske, M.D., Principal Investigator of the redePHine study.
06 Oct 2025 According to a Chiesi media release, Arbor and Chiesi will collaborate on the ongoing Phase 1/2 redePHine (NCT06839235) clinical study of ABO-101 in PH1.
30 Jul 2025 According to an Arbor Biotechnologies media release, dose escalation ongoing with enrollment at Mayo Clinic in the US and plans to open additional sites in the UK and EU in Q3 of this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com